BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19104697)

  • 1. Costs and efficacy of "on demand" low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation.
    Iacob S; Hrehoret D; Matei E; Dorobantu B; Gangone E; Gheorghe L; Popescu I
    J Gastrointestin Liver Dis; 2008 Dec; 17(4):383-8. PubMed ID: 19104697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
    Ferretti G; Merli M; Ginanni Corradini S; Callejon V; Tanzilli P; Masini A; Ferretti S; Iappelli M; Rossi M; Rivanera D; Lilli D; Mancini C; Attili A; Berloco P
    Transplant Proc; 2004 Apr; 36(3):535-8. PubMed ID: 15110584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
    Liu J; Wu GC; Zhang ZT; Wu P; Zhang D; Sun MC; Gao DC; Wang Y; Jia JD; Wang BE
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):976-9. PubMed ID: 16194352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.
    Samuel D; Zignego AL; Reynes M; Feray C; Arulnaden JL; David MF; Gigou M; Bismuth A; Mathieu D; Gentilini P
    Hepatology; 1995 Feb; 21(2):333-9. PubMed ID: 7843702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin.
    Terrault NA; Zhou S; Combs C; Hahn JA; Lake JR; Roberts JP; Ascher NL; Wright TL
    Hepatology; 1996 Dec; 24(6):1327-33. PubMed ID: 8938155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
    Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
    Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation in European patients with the hepatitis B surface antigen.
    Samuel D; Muller R; Alexander G; Fassati L; Ducot B; Benhamou JP; Bismuth H
    N Engl J Med; 1993 Dec; 329(25):1842-7. PubMed ID: 8247035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.
    Dickson RC; Terrault NA; Ishitani M; Reddy KR; Sheiner P; Luketic V; Soldevila-Pico C; Fried M; Jensen D; Brown RS; Horwith G; Brundage R; Lok A
    Liver Transpl; 2006 Jan; 12(1):124-33. PubMed ID: 16382463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation.
    Di Paolo D; Tisone G; Piccolo P; Lenci I; Zazza S; Angelico M
    Transplantation; 2004 Apr; 77(8):1203-8. PubMed ID: 15114086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulminant hepatitis B virus: recurrence after liver transplantation in two patients also infected with hepatitis delta virus.
    Marsman WA; Wiesner RH; Batts KP; Poterucha JJ; Porayko MK; Niesters HG; Zondervan PE; Krom RA
    Hepatology; 1997 Feb; 25(2):434-8. PubMed ID: 9021960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
    Lo CM; Liu CL; Chan SC; Lau GK; Fan ST
    J Hepatol; 2005 Aug; 43(2):283-7. PubMed ID: 15964658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
    Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
    Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of liver transplantation for hepatitis B: a single-center study of 35 patients.
    Benner A; Lyden E; Rogge J; Weaver L; Mukherjee S
    Transplant Proc; 2004 Nov; 36(9):2741-3. PubMed ID: 15621137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
    Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
    Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation.
    Takaki A; Yagi T; Iwasaki Y; Sadamori H; Matsukawa H; Matsuda H; Shinoura S; Umeda Y; Miyake Y; Terada R; Kobashi H; Sakaguchi K; Tanaka N; Shiratori Y
    Transplantation; 2007 Jan; 83(2):231-3. PubMed ID: 17264822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.
    Woo HY; Choi JY; Jang JW; You CR; Bae SH; Yoon SK; Yang JM; Choi SW; Han NI; Kim DG
    J Med Virol; 2008 Nov; 80(11):1891-9. PubMed ID: 18814257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.